2022
Combination laser interstitial thermal therapy plus stereotactic radiotherapy increases time to progression for biopsy-proven recurrent brain metastases
Grabowski MM, Srinivasan ES, Vaios EJ, Sankey EW, Otvos B, Krivosheya D, Scott A, Olufawo M, Ma J, Fomchenko EI, Herndon JE, Kim AH, Chiang VL, Chen CC, Leuthardt EC, Barnett GH, Kirkpatrick JP, Mohammadi AM, Fecci PE. Combination laser interstitial thermal therapy plus stereotactic radiotherapy increases time to progression for biopsy-proven recurrent brain metastases. Neuro-Oncology Advances 2022, 4: vdac086. PMID: 35795470, PMCID: PMC9248774, DOI: 10.1093/noajnl/vdac086.Peer-Reviewed Original ResearchLaser interstitial thermal therapyRecurrent brain metastasesBrain metastasis recurrenceKarnofsky performance statusBrain metastasesStereotactic radiotherapyLesion progressionInterstitial thermal therapyMetastasis recurrenceEfficacy of LITTNeuro-Oncology Brain Metastases criteriaSRT failurePercent of patientsAcademic medical centerContrast-enhancing volumeMetastasis (TNM) criteriaOpen resectionPerformance statusProspective trialMedian timeRetrospective studyTumor recurrenceInclusion criteriaMedical CenterEffective treatment
2015
Extended Survival and Prognostic Factors for Patients With ALK-Rearranged Non–Small-Cell Lung Cancer and Brain Metastasis
Johung KL, Yeh N, Desai NB, Williams TM, Lautenschlaeger T, Arvold ND, Ning MS, Attia A, Lovly CM, Goldberg S, Beal K, Yu JB, Kavanagh BD, Chiang VL, Camidge DR, Contessa JN. Extended Survival and Prognostic Factors for Patients With ALK-Rearranged Non–Small-Cell Lung Cancer and Brain Metastasis. Journal Of Clinical Oncology 2015, 34: 123-129. PMID: 26438117, PMCID: PMC5070549, DOI: 10.1200/jco.2015.62.0138.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAnaplastic Lymphoma KinaseAntineoplastic AgentsBrain NeoplasmsCarbazolesCarcinoma, Non-Small-Cell LungCranial IrradiationCrizotinibDisease-Free SurvivalFemaleFollow-Up StudiesGene RearrangementHumansKaplan-Meier EstimateKarnofsky Performance StatusLung NeoplasmsMaleMiddle AgedMolecular Targeted TherapyNeoplasm StagingPiperidinesPrognosisProtein Kinase InhibitorsProtein-Tyrosine KinasesPyrazolesPyridinesPyrimidinesRadiosurgeryReceptor Protein-Tyrosine KinasesRisk AssessmentRisk FactorsSmokingSulfonesConceptsIntracranial progression-free survivalBrain metastasesProgression-free survivalPrognostic factorsLung cancerMedian intracranial progression-free survivalNon-small cell lung cancerTyrosine kinase inhibitor therapyProgressive brain metastasesRefinement of prognosisKarnofsky performance scorePercent of patientsClinical prognostic factorsPopulation of patientsSingle brain metastasisCell lung cancerKinase inhibitor therapyCox proportional hazardsMulti-institutional studyMedian OSExtracranial metastasesImproved survivalInhibitor therapyInitial treatmentMultivariable analysis
2013
Gamma Knife radiosurgery for the management of nonfunctioning pituitary adenomas: a multicenter study.
Sheehan JP, Starke RM, Mathieu D, Young B, Sneed PK, Chiang VL, Lee JY, Kano H, Park KJ, Niranjan A, Kondziolka D, Barnett GH, Rush S, Golfinos JG, Lunsford LD. Gamma Knife radiosurgery for the management of nonfunctioning pituitary adenomas: a multicenter study. Journal Of Neurosurgery 2013, 119: 446-56. PMID: 23621595, DOI: 10.3171/2013.3.jns12766.Peer-Reviewed Original ResearchConceptsPrior radiation therapyPituitary adenomasTumor controlNonfunctional pituitary adenomasNerve dysfunctionRadiation therapyNorth American Gamma Knife ConsortiumActuarial tumor controlDegree of hypopituitarismMulticenter patient populationTime of radiosurgeryCranial nerve deficitsPercent of patientsCranial nerve functionOptic nerve dysfunctionCranial nerve dysfunctionGamma Knife surgeryManagement of patientsOverall tumor controlGamma knife radiosurgeryExternal beam radiotherapyProgressive cranial nerve deficitsCommon intracranial neoplasmsDelayed hypopituitarismMargin doses